BB's Stock Haven

[Walker]

DD on PLBI - Stem Cell Play:

PLBI - Some Info:

The new CEO - Armando Casciati - is a major player:

Mr. Casciati is the owner and operator of the $40 million dollar waterfront resort Sosua Bay Resort and the new building being constructed for the Sosua Bay Grand Casino. Mr. Casciati was born in Italy and brings tremendous value to the company through his knowledge and current operations within Sosua that he has been involved with for nearly 10 years. Mr. Casciati is a large residential and commercial property owner within Sosua, he owns a TV Station, a large diaper factory, and owns and operates the most popular nightclub “Classico” in Sosua.

http://www.sosuabayresort.com/main-index.htm

http://www.sosuabayresort.com/sosua-bay-beach-club.html

http://www.sosuabayresort.com/victorian-house-hotel-index.htm


Here is the website of the new company m,erging into PLBI:

http://www.regenobody.com/

They are very big and very well known in the Dominican Republic


PLBI - recent news:

Proton Laboratories, Inc. Announces the Acquisition of Regenobody S.A.

SOSUA BAY, Dominican Republic, Jan 8, 2010 (GlobeNewswire via COMTEX) -- Proton Laboratories, Inc. (Pink Sheets:PLBI), a Washington corporation, today announced the acquisition of Regenobody S.A., a Dominican Republic company involved in some of the latest technologies associated with stem cell regeneration using the patient's own stem cells. Pursuant to the Agreement, the Company (PLBI) will issue 300,000,000 of its common shares to the Regenobody shareholders, which will result in the shareholders of Regenobody acquiring shareholder control of Proton Laboratories, Inc.
Armando Casciati, newly elected President of Proton Laboratories, Inc. stated that the new company will aggressively work toward completing the development of its laboratory and acquisition of the balance of the needed equipment from its Korean licensor and patent holder, RNLBIO. It is anticipated that a name change and symbol change will occur in the next 90 days. The prior Proton directors have resigned concurrent with the acquisition. More information may be seen at the Company's website www.regenobody.com.


Regenobody S.A. Obtains License From the Dominican Republic to Harvest, Incubate, and Transplant Stem Cells

SOSUA BAY, Dominican Republic, Jan 12, 2010 (GlobeNewswire via COMTEX) -- Proton Laboratories, Inc. (Pink Sheets:PLBI), through the newly acquired Regenobody S.A, has obtained a license, through LifeXtension Worldwide, from the Government of the Dominican Republic for harvesting, incubating, and transplanting stems cells.
Armando Casciati, President of Proton Laboratories, Inc., stated; "This is tremendous news for our company. Very rarely are companies licensed by their respective governments to conduct research, harvest, and incubate stems cells while then being able to transplant these cells back to the patients for therapeutic benefit." Regenobody S.A. will be utilizing procedures and equipment obtained through an EXCLUSIVE Caribbean license from its Korean licensor and patent holder, RNL BIO Co. Ltd. Prior to Regenobody S.A. obtaining the EXCLUSIVE Caribbean licensing rights, these procedures were only available in Japan, Korea, and China. More information may be seen at the Company's website www.regenobody.com. Mr. Casciati went on to state that; "We are focused on developing a world class facility with world class equipment, technicians and procedures to allow patients the ability to utilize their own stem cells, mainly obtained through the fatty tissues of the stomach, to improve their lives."


RNL Bio to initiate stem cell human trial for spinal cord injury



Singapore, May 12, 2009: Korean company, RNL Bio, a leader in adult stem cell therapeutics, has announced that the Korean FDA has approved its human clinical study to treat patients with spinal cord injury using ‘RNL-Astrostem’, which is based on fat derived adult stem cells.


RNL Bio is said to have presented its three years’ preclinical trial results showing perfect safety profile and remarkable efficacy potential. RNL was approved to begin phase I human trial using these adult stem cells and it is the world first trial to treat spinal cord injury with adult stem cells derived patients’ own fat tissue.


RNL-Astrostem is administered by intravenous infusion so patients don’t have to worry about any invasive and painful surgical procedure. Dr Jeong Chan Ra, CEO, RNL Bio said “Our stem cell therapeutics involves no immune rejection because the stem cells are exactly patients own. Our adult stem cell has no tumorigenicity activity at all while embryonic stem cell faces high risk of it. We have developed safest therapeutics to help devastated patients with incurable diseases."


Very informative YouTube video on RNL Bio:

PLBI - Here is the company they are working with - Exclusive License:

RNL BIO - https://rnl.co.kr/eng/main.asp


RNL Biostar Opens Stem Cell R&D and Manufacturing Facility
Will Add 50 Jobs in Next 3 Years

RNL Biostar formally opened on August 25 its new 4,000 square-foot stem cell R&D and manufacturing facility at the Germantown Innovation Center (GIC), the County’s fifth and newest incubator facility that opened last fall as part of the Montgomery County Business Innovation Network (BIN).

Montgomery County Department of Economic Development Director Steve Silverman and Maryland State Senator Jennie M. Forehand joined RNL Biostar executives and other local and state officials and private sector guests in celebrating the event.

Montgomery County Executive Isiah Leggett said, “I congratulate RNL Biostar on the opening of its new, expanded facility at the County’s Germantown Innovation Center and wish them continued success in their work to combat such debilitating ailments as Buerger’s Disease, degenerative arthritis and spinal cord injuries using unique stem cell therapies.”

He added: “I visited RNL Bio during my business development mission to Korea last fall and saw firsthand their vital stem cell therapy research and development. We are delighted that RNL Biostar’s expansion in the county will help further this important work while adding jobs to our local economy. It’s a win-win for everyone.”

“The expansion of RNL Biostar demonstrates the highly supportive environment and tremendous assets found within the State to advance our bioscience industry,” said Governor Martin O’Malley. “The opening of the new Maryland Biotechnology Center, along with key recommendations from Maryland’s Life Sciences Advisory Board, will support future company growth around the State as part of our BioMaryland 2020 initiative.”

RNL Biostar, a wholly-owned subsidiary of premier Korean biotechnology company RNL Bio, was attracted to the County’s Maryland Technology Development Center incubator in 2006. The company is responsible for US clinical development and licensing its technologies in the North and South American markets.

The company, which plans to grow from four current employees to more than 50 within the next three years, first announced its expansion plans during the Biotechnology Industry Organization (BIO) International Conference in May in Atlanta.

RNL Biostar joins 22 other GIC companies that have established or expanded a presence in the county because of numerous business assets, including 300-plus biotech companies, 19 federal research and regulatory agencies, nearly 60,000 public and private sector life sciences professionals and the highest per capita concentration of PhDs in the nation. The addition of RNL Biostar brings the GIC’s occupancy rate to nearly 90 percent since opening in November.

RNL Biostar invested $6 million for equipment purchase and facility improvements, including five offices, four clean rooms and one lab. The County provided the company with a $230,000 Economic Development Fund grant to help support its growth from six current employees to more than 50 full-time positions within the next three years. The majority of these new positions will be cell manufacturing technicians averaging $50,000/year, and RNL Biostar plans to occupy 20,000 square feet of commercial space in the county by late 2014.

“I’m excited to be here today from Korea to help celebrate the opening of our new, expanded stem cell facility in Montgomery County,” said Dr. Jeong Chan Ra, chief executive officer of RNL Bio and RNL Biostar.

He added: “This impressive new facility will enable us to further our stem cell technology aimed at alleviating incurable diseases like Buerger’s Disease and degenerative arthritis and allow us to aggressively pursue other strategic company goals, like further development of our unique fat-based stem cells. We look forward to continued success in these and other areas from our new space here at the Germantown Innovation Center.”

RNL Bio, headquartered in Seoul, Korea and publicly traded on the Korean Stock Exchange, is focused on the research and development of adult derived stem cell therapies and life sciences technologies. RNL has two therapies in Phase II clinical trials, one for Buerger's Disease and one for osteoarthritis. RNL Biostar is responsible for clinical development in the U.S. and for licensing its technologies in North and South American markets.